MAIA Biotechnology, Inc. announced that the World Intellectual Property Organization (WIPO) has published MAIA?s global Patent Cooperation Treaty (PCT) application titled ?Dinucleotides and Their Use in Treating Cancer.? These compounds are key next-generation telomere-targeting agents, an important extension of MAIA?s innovative cancer treatment platform. The international patent application covers potential cancer therapies using dinucleotide compounds that target telomeres in cancer cells, and methods for using the dinucleotide compounds to treat cancers alone or before administration with checkpoint inhibitors (CPIs).

The new dinucleotides disclosed in the patent application are telomere-targeting molecules, such as THIO fragments or other THIO analogues. The PCT system streamlines the process for obtaining patent protection globally. Under the PCT, applicants can seek patent protection in a large number of countries.